Collegium Pharmaceutical, Inc. (COLL)
NASDAQ: COLL · Real-Time Price · USD
26.94
-0.08 (-0.30%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Collegium Pharmaceutical Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Collegium Pharmaceutical stock have an average target of 43.6, with a low estimate of 36 and a high estimate of 50. The average target predicts an increase of 61.84% from the current stock price of 26.94.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Collegium Pharmaceutical stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $46 | Strong Buy | Reiterates | $46 | +70.75% | Apr 9, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +85.60% | Mar 24, 2025 |
| Piper Sandler | Piper Sandler | Hold Maintains $37 → $36 | Hold | Maintains | $37 → $36 | +33.63% | Feb 4, 2025 |
| Needham | Needham | Hold → Strong Buy Upgrades $46 | Hold → Strong Buy | Upgrades | $46 | +70.75% | Jan 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +85.60% | Jan 10, 2025 |
Financial Forecast
Revenue This Year
757.47M
from 631.45M
Increased by 19.96%
Revenue Next Year
787.25M
from 757.47M
Increased by 3.93%
EPS This Year
7.05
from 1.86
Increased by 279.47%
EPS Next Year
7.44
from 7.05
Increased by 5.58%
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 785.3M | 837.5M | 870.1M | ||
| Avg | 757.5M | 787.3M | 734.1M | ||
| Low | 724.7M | 730.6M | 576.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 24.4% | 10.6% | 10.5% | ||
| Avg | 20.0% | 3.9% | -6.8% | ||
| Low | 14.8% | -3.5% | -26.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 7.74 | 8.42 | 9.08 | |
| Avg | 7.05 | 7.44 | 6.49 | |
| Low | 6.53 | 6.16 | 3.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 316.8% | 19.5% | 22.1% | |
| Avg | 279.5% | 5.6% | -12.8% | |
| Low | 251.5% | -12.5% | -50.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.